Browse Prior Art Database

(3R, 4S)-4-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-2-Azetidinone Disclosure Number: IPCOM000125170D
Publication Date: 2005-May-23
Document File: 1 page(s) / 99K

Publishing Venue

The Prior Art Database

This text was extracted from a PDF file.
At least one non-text object (such as an image or picture) has been suppressed.
This is the abbreviated version, containing approximately 100% of the total text.

Page 1 of 1

 (3R, 4S)-4-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-3-[(3S)-3-(4- fluorophenyl)-3-hydroxypropyl]-2-Azetidinone _________________________________________________________

(3R, 4S)-4-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl]-2-Azetidinone (BZT) is used as intermediate in the preparation of Ezetimibe.

Its chemical formula is:







BZT was produced according to the basic patent US 5,631,365.

According to the XRD, BZT contains crystal forms 01.

Form 01 may be identified by an X-ray powder diffraction pattern with peaks at: 6.1,
16.3, 18.3, 19.6, 20.1, 20.3, 21.0, 21.7, 23.8, 25.3 degrees two-theta, ± 0.2 degrees two-theta.

X-Ray Powder Diffractions were performed on ARL (Scintag) X-Ray powder diffractometer model X'TRA, Cu-tube, solid state detector. A round standard aluminum sample holder with round zero background quartz plate was used. Scanning parameters: range 2-40 deg.2θ, continuous scan, rate 3 deg/min.


Crystal form 01

[This page contains 2 pictures or other non-text objects]